Cargando…
Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development
Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999086/ https://www.ncbi.nlm.nih.gov/pubmed/35409840 http://dx.doi.org/10.3390/ijerph19074156 |
_version_ | 1784685106567315456 |
---|---|
author | Paczkowska-Walendowska, Magdalena Sip, Szymon Staszewski, Rafał Cielecka-Piontek, Judyta |
author_facet | Paczkowska-Walendowska, Magdalena Sip, Szymon Staszewski, Rafał Cielecka-Piontek, Judyta |
author_sort | Paczkowska-Walendowska, Magdalena |
collection | PubMed |
description | Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using β-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and/or in patients with coexistence of other diseases. |
format | Online Article Text |
id | pubmed-8999086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89990862022-04-12 Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development Paczkowska-Walendowska, Magdalena Sip, Szymon Staszewski, Rafał Cielecka-Piontek, Judyta Int J Environ Res Public Health Review Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using β-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and/or in patients with coexistence of other diseases. MDPI 2022-03-31 /pmc/articles/PMC8999086/ /pubmed/35409840 http://dx.doi.org/10.3390/ijerph19074156 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Paczkowska-Walendowska, Magdalena Sip, Szymon Staszewski, Rafał Cielecka-Piontek, Judyta Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title | Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title_full | Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title_fullStr | Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title_full_unstemmed | Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title_short | Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development |
title_sort | single-pill combination to improve hypertension treatment: pharmaceutical industry development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999086/ https://www.ncbi.nlm.nih.gov/pubmed/35409840 http://dx.doi.org/10.3390/ijerph19074156 |
work_keys_str_mv | AT paczkowskawalendowskamagdalena singlepillcombinationtoimprovehypertensiontreatmentpharmaceuticalindustrydevelopment AT sipszymon singlepillcombinationtoimprovehypertensiontreatmentpharmaceuticalindustrydevelopment AT staszewskirafał singlepillcombinationtoimprovehypertensiontreatmentpharmaceuticalindustrydevelopment AT cieleckapiontekjudyta singlepillcombinationtoimprovehypertensiontreatmentpharmaceuticalindustrydevelopment |